Approval · Notice of Compliance 3082 · 1998
SERZONE: Notice of Compliance 3082
Issued August 13, 1998
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3082
- Date
- August 13, 1998
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Provides for a change in initial dosing, pm update
- Therapeutic class
- Antidepressant
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SERZONE | Not yet assigned | — |
Medicinal ingredients
- NEFAZODONE HCL 50 MG per TAB
- NEFAZODONE HCL 150 MG per TAB
- NEFAZODONE HCL 100 MG per TAB
- NEFAZODONE HCL 200 MG per TAB
- NEFAZODONE HCL 300 MG per TAB